Invesaro

Stocks ARQT Earnings

Earnings

Arcutis Biotherapeutics, Inc. (ARQT) earnings

Quarterly results of Arcutis Biotherapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when ARQT files with the SEC.

Next earnings date

Arcutis Biotherapeutics, Inc. is expected to report around February 24, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

Latest quarter: Q3 FY2026

In Q3 FY2026 (ended September 30, 2026) Arcutis Biotherapeutics, Inc. reported revenue of $143.9M (+45.1% on the same quarter a year earlier) and net income of $8.8M (+18.8% on the same quarter a year earlier).

Diluted earnings per share were $0.06 (+0% on the same quarter a year earlier).

Filed with the SEC on November 4, 2026.

Revenue by quarter
Q4 24: $71.4M $71.4M Q4 24Q1 25: $65.8M $65.8M Q1 25Q2 25: $81.5M $81.5M Q2 25Q3 25: $99.2M $99.2M Q3 25Q4 25: $129.5M $129.5M Q4 25Q1 26: $105.4M $105.4M Q1 26Q2 26: $129.9M $129.9M Q2 26Q3 26: $143.9M $143.9M Q3 26
Net income by quarter
Q4 24: -$10.8M -$10.8M Q4 24Q1 25: -$25.1M -$25.1M Q1 25Q2 25: -$15.9M -$15.9M Q2 25Q3 25: $7.4M $7.4M Q3 25Q4 25: $17.4M $17.4M Q4 25Q1 26: -$11.3M -$11.3M Q1 26Q2 26: $15M $15M Q2 26Q3 26: $8.8M $8.8M Q3 26

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q3 FY2026September 30, 2026$143.9M+45.1%$8.8M$0.06
Q2 FY2026June 30, 2026$129.9M+59.3%$15M$0.11
Q1 FY2026March 31, 2026$105.4M+60.1%-$11.3M-$0.09
Q4 FY2025December 31, 2025$129.5M+81.5%$17.4M-
Q3 FY2025September 30, 2025$99.2M-$7.4M$0.06
Q2 FY2025June 30, 2025$81.5M--$15.9M-$0.13
Q1 FY2025March 31, 2025$65.8M--$25.1M-$0.20
Q4 FY2024December 31, 2024$71.4M--$10.8M-

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Results filings

When is Arcutis Biotherapeutics, Inc.'s next earnings date?

Arcutis Biotherapeutics, Inc. is expected to report around February 24, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

What were Arcutis Biotherapeutics, Inc.'s latest quarterly results?

For Q3 FY2026, which ended September 30, 2026, Arcutis Biotherapeutics, Inc. reported revenue of $143.9M and net income of $8.8M (+18.8% on the same quarter a year earlier). The figures come from its filing with the SEC.

Is Arcutis Biotherapeutics, Inc.'s revenue growing?

Revenue in Q3 FY2026 was $143.9M, up 45.1% from $99.2M in the same quarter a year earlier.

Get an email when ARQT reports

Follow ARQT and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when ARQT files with the SEC.

Source: quarterly figures Arcutis Biotherapeutics, Inc. tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about Arcutis Biotherapeutics, Inc.